Glembatumumab vedotin (GV) is an antibody–drug conjugate consisting of a gpNMB-specific monoclonal antibody coupled to the microtubule inhibitor monomethyl auristatin E (MMAE) [260] that has shown effect in the treatment of gpNMB-expressing breast cancer [262]. The gene discussed is GPNMB; the disease is breast carcinoma.